<p>Relapse is currently the major cause of death in children with B-ALL. The goal of this study is to uncover the genetic underpinnings of relapsed B-ALL in the <a href="https://childrensoncologygroup.org/aall1331">AALL1331</a> cohort (PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33651090/">33651090</a>) via whole genome and transcriptome sequencing of matched diagnosis, relapse, and remission specimens. We aim to discover genetic alterations that drive treatment resistance in relapsed tumors. We also aim to investigate the feasibility of detecting residual tumors from remission samples with the ultimate goal to improve risk stratification using NGS-based minimal residual disease (MRD) detection. Here we only report data from patients in remission with the aim of determining MRD. We will submit corresponding data for the diagnosis and relapse components of our cohort in a future version of our study.</p>

Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic    Leukemia

1 selected publication including "Effect of Postreinduction Therapy Consolidation With Blinatumomab vs C..." (277 citations)

Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.